Work

Phase II Study of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Refractory or Recurrent Hodgkin’s Disease.

Year: 2004

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v104.11.2635.2635

Authors: John P. Leonard, Joseph D. Rosenblatt, Nancy L. Bartlett, Ajay Gopal, Anas Younes, David Fisher, Francine Foss, Andres Forero, Steven Bernstein, Bruce Cheson, Matthew H. Carabasi, R. Gregory Bociek, Bruce Hart, Michael McDonald

Institutions: Cornell University, Weill Cornell Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Washington University in St. Louis, Seattle Cancer Care Alliance, University of Washington, The University of Texas MD Anderson Cancer Center, Dana-Farber Cancer Institute, Tufts Medical Center, University of Alabama at Birmingham, University of Rochester Medicine, University of Rochester, Georgetown University Medical Center, University of Southern California, USC Norris Comprehensive Cancer Center, University of Nebraska Medical Center, Seagen (United States)

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2993726255

FWCI: 3.168

Cites:

Cited by: 25

Related to: 10